GBIO

Generation Bio Co. (GBIO) | Rumor.io

Generation Bio

GBIO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)40%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about GBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 16

Generation Bio Co. ($GBIO) has been acquired by Xoma Royalty in an all-cash deal at $4.2913 per share, with stockholders also receiving a contingent value right.
Analysts have upgraded Generation Bio, with Wedbush setting a target price of $5.5 and Jefferies maintaining a Hold rating with a price target of $5.
The acquisition price represents a 20.53% discount from Generation Bio's last close, and some critics question the company's decision to fire 90% of its workers, citing potential risks to core drug programs and shareholder value.

Generated by AI

Sentiment

Of the messages about GBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.47% +17.62
Bearish	—	—	—	11.53% -17.62

Bullish· Aug 15

Generation Bio Co. ($GBIO) has shown strong momentum in recent trading, with potential for further gains.
The stock has been following a solid upward trend, with a target price of $20-$25 in the near future.
$GBIO is a strong momentum play, with investors encouraged to stay tuned for further updates on its potential for growth.

Bearish· Aug 13

Generation Bio is shedding 90% of its workforce due to a cash crunch, potentially rendering the biotech unable to support clinical development for its lipid nanoparticle platform.
The company's recent pump may be short-lived, with the stock likely to drop to the $4.50-4.65 range due to a lack of revenue and a history of trading around this price.
The stock's recent run is driven by momentum and scanner hype, with the company still bleeding cash and years away from having a product approved by the FDA, making it a high-risk bet for investors.

Generated by AI

Topics

Of the messages about GBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	3.95%
Announcements	—	100%	100%	77.75%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	3.12%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	15.18%

Analysts· Dec 15

Needham analyst Gil Blum maintains Generation Bio with a Buy rating and lowers the price target from $50 to $27.
JMP Securities analyst Silvan Tuerkcan maintains Generation Bio with a Market Outperform rating and lowers the price target from $40 to $10.
JP Morgan Chase downgrades Generation Bio to Neutral from Overweight.

Announcements· Aug 15

Generation Bio Co. reported Q2 revenue of $0.78M, a decline of 81% YoY, and a net loss of $20.9M.
The company reduced its workforce by 90% and is exploring strategic alternatives to drive growth.
Generation Bio's ctLNP system achieved first-ever siRNA delivery to T-cells in primates, a key milestone for the company.

Generated by AI

Community

Of the messages about GBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	19.61%
Newcomers	—	100%	100%	80.39%

Regulars· Mar 23

$GBIO's stock surged 14.7% pre-market after announcing a strategic collaboration with Moderna to develop non-viral genetic medicines, with Generation Bio receiving a $40M upfront payment.
The partnership between $GBIO and Moderna is seen as a significant move in the genetic medicine space, with $GBIO's ctLNP tech being a key piece in the puzzle for in vivo gene editing.
The collaboration between $GBIO and Moderna will combine their expertise to develop non-viral genetic medicines, with $GBIO's non-viral genetic medicine platform being a key focus of the partnership.

Newcomers· Aug 18

Generation Bio Co. is now an event-driven play, with its future dependent on a strategic deal rather than its R&D.
The company is cash-rich but has halted operations, offering upside only if management unlocks value through M&A or asset sale.
The focus is on preserving capital, as the company's value hinges on its ability to unlock value through a strategic deal.

Generated by AI

Also Discussed

Investors talking about GBIO also mention

#	Name	Attention
1	MRSN - Mersana Therapeutics, Inc.	——
2	ProKidney Corp. Class A Ordinary SharesPROK	0%0
3	BSLK - Bolt Projects Holdings, Inc.	——
4	Arvinas, Inc.ARVN	0%+0
5	Cognition Therapeutics, Inc.CGTX	0%+0
6	Mega Matrix Inc.MPU	0%0
7	BG Staffing IncBGSF	0%new
8	IO Biotech, Inc.IOBT	0%0
9	Palvella Therapeutics, Inc.PVLA	0%new
10	Neurogene Inc.NGNE	0%0

Generation Bio Co.

Location

Social

What share of all stock conversation is about GBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 16

Generation Bio Co. ($GBIO) has been acquired by Xoma Royalty in an all-cash deal at $4.2913 per share, with stockholders also receiving a contingent value right.
Analysts have upgraded Generation Bio, with Wedbush setting a target price of $5.5 and Jefferies maintaining a Hold rating with a price target of $5.
The acquisition price represents a 20.53% discount from Generation Bio's last close, and some critics question the company's decision to fire 90% of its workers, citing potential risks to core drug programs and shareholder value.

Generated by AI

Sentiment

Of the messages about GBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.47% +17.62
Bearish	—	—	—	11.53% -17.62

Bullish· Aug 15

Generation Bio Co. ($GBIO) has shown strong momentum in recent trading, with potential for further gains.
The stock has been following a solid upward trend, with a target price of $20-$25 in the near future.
$GBIO is a strong momentum play, with investors encouraged to stay tuned for further updates on its potential for growth.

Bearish· Aug 13

Generation Bio is shedding 90% of its workforce due to a cash crunch, potentially rendering the biotech unable to support clinical development for its lipid nanoparticle platform.
The company's recent pump may be short-lived, with the stock likely to drop to the $4.50-4.65 range due to a lack of revenue and a history of trading around this price.
The stock's recent run is driven by momentum and scanner hype, with the company still bleeding cash and years away from having a product approved by the FDA, making it a high-risk bet for investors.

Generated by AI

Topics

Of the messages about GBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	3.95%
Announcements	—	100%	100%	77.75%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	3.12%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	15.18%

Analysts· Dec 15

Needham analyst Gil Blum maintains Generation Bio with a Buy rating and lowers the price target from $50 to $27.
JMP Securities analyst Silvan Tuerkcan maintains Generation Bio with a Market Outperform rating and lowers the price target from $40 to $10.
JP Morgan Chase downgrades Generation Bio to Neutral from Overweight.

Announcements· Aug 15

Generation Bio Co. reported Q2 revenue of $0.78M, a decline of 81% YoY, and a net loss of $20.9M.
The company reduced its workforce by 90% and is exploring strategic alternatives to drive growth.
Generation Bio's ctLNP system achieved first-ever siRNA delivery to T-cells in primates, a key milestone for the company.

Generated by AI

Community

Of the messages about GBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	19.61%
Newcomers	—	100%	100%	80.39%

Regulars· Mar 23

$GBIO's stock surged 14.7% pre-market after announcing a strategic collaboration with Moderna to develop non-viral genetic medicines, with Generation Bio receiving a $40M upfront payment.
The partnership between $GBIO and Moderna is seen as a significant move in the genetic medicine space, with $GBIO's ctLNP tech being a key piece in the puzzle for in vivo gene editing.
The collaboration between $GBIO and Moderna will combine their expertise to develop non-viral genetic medicines, with $GBIO's non-viral genetic medicine platform being a key focus of the partnership.

Newcomers· Aug 18

Generation Bio Co. is now an event-driven play, with its future dependent on a strategic deal rather than its R&D.
The company is cash-rich but has halted operations, offering upside only if management unlocks value through M&A or asset sale.
The focus is on preserving capital, as the company's value hinges on its ability to unlock value through a strategic deal.

Generated by AI

Generation Bio

Social

Dec 16

Sentiment

Bullish· Aug 15

Bearish· Aug 13

Topics

Analysts· Dec 15

Announcements· Aug 15

Community

Regulars· Mar 23

Newcomers· Aug 18

Also Discussed

Generation Bio Co.

Company Information

Location

Also Discussed

Social

Dec 16

Sentiment

Bullish· Aug 15

Bearish· Aug 13

Topics

Analysts· Dec 15

Announcements· Aug 15

Community

Regulars· Mar 23

Newcomers· Aug 18